‘The evidence PANORAMIC has produced about molnupiravir will guide treatment decisions for COVID-19 world-wide. A total of 25,786 study participants were randomly assigned to receive either molnupiravir or the usual standard of NHS care. 50 (0·4%) participants experienced serious adverse events in the molnupiravir group and 45 (0·4%) in usual care. Patients in a sub-group treated with molnupiravir showed reduced viral detection and viral load on Day 7. ‘I’m delighted to see how our recruitment strategy has been hugely successful across all ethnicities and areas of high deprivation.
